EyePoint Pharmaceuticals, Inc.
Omeros Corporation
Ocular Therapeutix
Alcon Vision, LLC
Bausch + Lomb
Carl Zeiss Meditec
EyePoint Pharmaceuticals, Inc.
Omeros Corporation
Join moderators Leon Herndon, MD and Nathan Radcliffe, MD, and expert faculty in a discussion and comparison of new and emerging options in glaucoma procedures and treatment.
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Begin Online CME Activity Now
EyePoint Pharmaceuticals, Inc.
Omeros Corporation
Ocular Therapeutix
Alcon Vision, LLC
Bausch + Lomb
Carl Zeiss Meditec
EyePoint Pharmaceuticals, Inc.
Omeros Corporation
Sumit “Sam” Garg, MD
● Benefits from both Surgeon and Patient Perspective
● Consequences of inadequate management
● Complications after Cataract Surgery
Neda Shamie, MD
● CME
● Effectiveness of products on the incidence of these issues
Eric Donnenfeld, MD
● Pearls for Using the New Drug Delivery Medications
○ Including combining them into defined regimens
○ Cataract Experience for Patient and Surgeon
○ Associated Costs
Denise Visco, MD
- Compare and contrast current and emerging regimens and pharmaceutical approaches for the prevention of pain and inflammation in cataract surgery, including alternative therapeutic options designed to overcome patient compliance concerns and reduce ocular toxicity.
- Determine adjustments needed to pre, intra, and postoperative steroid and NSAID regimens for patients at greater risk for inflammation.
- Discuss cataract patients’ perceptions of intra-and postoperative pain and the impact that it has on surgical outcomes and patient satisfaction.
- Describe evolving reimbursement models to expand access to new approaches to control pain and inflammation after cataract surgery.
Accreditation Statement
The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.
Designation Statement
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Educational Objectives
Upon completion of the ASCRS Inflammation and Pain program, participants should be able to:
Claim CME/CE Credits
Attendees will be able to evaluate the Inflammation and Pain webinar electronically. At the conclusion of the program, attendees will be emailed a link to the program evaluation and credit claim. Please contact Janell John, ASCRS CME Coordinator, at jjohn@ascrs.org with any questions on credit claims.
Notice About Off-Label Use Presentations
The ASCRS Inflammation and Pain webinar may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.
ADA/Special Accommodations
ASCRS fully complies with the legal requirements of the American with Disabilities Act (ADA) and the rules and regulations thereof. ASCRS also requires ADA compliance from its contracted vendors and facilities. Any participant in this educational program who requires special accommodations or services should contact a staff member.
We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.